• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cryo-Cell International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    10/31/24 5:15:09 PM ET
    $CCEL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $CCEL alert in real time by email
    8-K
    false000086269200008626922024-10-292024-10-29

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 29, 2024

     

     

    CRYO-CELL INTERNATIONAL, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40767

    22-3023093

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    700 Brooker Creek Blvd.

     

    Oldsmar, Florida

     

    34677

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 813 749-2100

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.01 par value

     

    CCEL

     

    NYSE American LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On October 29, 2024, the Company held its Annual Meeting of Stockholders. At the Annual Meeting, stockholders considered the election of four directors, the ratification of the Company's independent registered accountants and the approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers

     

    The final result of the stockholder vote was certified on October 29, 2024 and is as follows:

     

    1. To consider the election of four individuals to the Company's Board of Directors.

     

    David Portnoy

    For 3,653,908

    Withhold 789,479

     

    Harold Berger

    For 3,628,143

    Withhold 815,244

     

    Mark Portnoy

    For 3,649,613

    Withhold 793,774

     

    Daniel Mizrahi

    For 4,072,486

    Withhold 370,901

     

    2. The ratification of appointment of WIPFLI LLC as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2024.

     

    For Against Abstain

    6,697,620 186 3,536

     

    3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers.

     

    For Against Abstain

    4,152,942 287,390 3,055

     

     

    4. Authorization to vote the proxies upon other business properly coming before the Meeting or any adjournments or postponements thereof.

     

    For Against Abstain

    3,571,034 855,538 16,814

     

     

    .


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    Cryo-Cell International, Inc.

     

     

     

     

    Date:

    October 31, 2024

    By:

    /s/ David Portnoy

     

     

     

    David Portnoy, Chairman and Co-CEO

     


    Get the next $CCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCEL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that

      5/8/25 5:00:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2025 Financial Results

      Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2025. Financial Results Revenue The revenues for the first quarter of fiscal 2025 were $7.97 million compared to $7.85 million for the first quarter of fiscal 2024. The revenues for the first quarter of fiscal 2025 consisted of $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately $82,000 in public banking revenue compared to $7.81 million in processing and storage fees, approximately $3,000 in product revenue and approximat

      4/15/25 8:30:00 AM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg

      1/29/25 4:15:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Information Officer Mikulinsky Oleg

      4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

      1/23/25 5:00:12 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by Chairman, Co-CEO Portnoy David

      4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

      1/23/25 5:00:05 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 4 filed by VP Finance, CFO Taymans Jill M

      4 - CRYO CELL INTERNATIONAL INC (0000862692) (Issuer)

      1/23/25 5:00:03 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    SEC Filings

    See more
    • Cryo-Cell International Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

      5/22/25 5:00:13 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cryo-Cell International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

      5/8/25 5:00:08 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Cryo-Cell International Inc.

      10-Q - CRYO CELL INTERNATIONAL INC (0000862692) (Filer)

      4/14/25 5:00:24 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Cryo-Cell International Announces Changes To Its Board of Directors

      MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NASDAQ:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and Mr. Daniel Mizrahi to the Company's Board of Directors, replacing Mr. George Gaines and Jonathan Wheeler, M.D., who have resigned in their capacity as Directors. Mr. Gaines has chosen to retire while Dr. Wheeler has resigned for health reasons. The Board of Directors voted unanimously in favor of adding Mr. Mark Portnoy and Mr. Daniel Mizrahi as members of the Board. Mr. Portnoy is a Co-CEO of the Company and previously served as a member of the Board of Directors from 2011-2020. Mr. Miz

      9/20/21 6:05:23 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

      SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)

      2/14/23 4:14:29 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Cryo-Cell International Inc. (Amendment)

      SC 13G/A - CRYO CELL INTERNATIONAL INC (0000862692) (Subject)

      2/14/22 12:44:18 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care

    $CCEL
    Financials

    Live finance-specific insights

    See more
    • Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that

      5/8/25 5:00:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors will continue to evaluate the Company's dividend policy on a regular basis and may change such policy at any time. There is no assurance that future dividends will be paid. The Company also announced that it has paused its strateg

      1/29/25 4:15:00 PM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care
    • Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend

      Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) ("Cryo-Cell"), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company's earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future di

      10/30/24 8:45:00 AM ET
      $CCEL
      Misc Health and Biotechnology Services
      Health Care